PRINCETON, N.J. — Dr. Reddy’s Laboratories announced the launch of sevelamer carbonate for oral suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for oral suspension, approved by the U.S. Food and Drug Administration.

The Renvela brand and generic had U.S. sales of approximately $101 million MAT for the most recent twelve months ending in October 2018 according to IMS Health.

Dr. Reddy’s sevelamer carbonate for oral suspension is available in 0.8 g and 2.4 g packets in count size of 90.